Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | Relevance of prognostic factors in the era of targeted therapies in CLL

Adam Kittai • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Adam Kittai, MD, Ohio State University, Columbus, OH discusses his recently published review in Current Hematologic Malignancy Reports on the relevance of prognostic factors in the era of targeted therapies in chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Adam Kittai

The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL 3:54
The uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for CLL
Adam Kittai • 12 Jun 2025
Recent developments in the treatment of Richter’s transformation 1:58
Recent developments in the treatment of Richter’s transformation
Adam Kittai • 12 Jun 2025
The ERIC recommendations for Richter’s transformation: guidelines for management & trial design 2:18
The ERIC recommendations for Richter’s transformation: guidelines for management & trial design
Adam Kittai • 12 Jun 2025
What’s on the horizon for patients with Richter’s transformation? 1:42
What’s on the horizon for patients with Richter’s transformation?
Adam Kittai • 10 Dec 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals